TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
TRINITY BIOTECH PLC
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026
$8.19+0.16 (+1.99%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
TRINITY BIOTECH PLC income statement
Ratios
Latest available, balances at Dec 31, 2025
Profitability, FY2025
- Gross margin
- 38.6%
- Operating margin
- -36.1%
- Net margin
- -85.4%
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 0.25
- Debt to equity
- –
- Debt to assets
- 0.2%
- Cash to current liabilities
- 3.6%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –